

Genovis' nanoparticle project published in prestigious Journal of Nuclear Medicine

The first scientific article from the Sentinel Node project was published in the Journal of Nuclear Medicine, a highly ranked journal in its field and a forum for the exchange of clinical and scientific information for nuclear medicine practitioners.

“The Sentinel Node project is a long-term project and it is wonderful to see the first results now published, which is proof of its scientific merit and newsworthiness. We appreciate the interdisciplinary partnership with Lund Biomedicine Center and the Department of Medical Radiation Physics. It provides us with an opportunity to test our nanostructures in a project backed by extremely concrete clinical support together with highly qualified, internationally recognized researchers. Publication also improves the visibility of our technology in the market. Earlier in January one of our customers published a stem cell study in which Genovis' nanostructures make it possible to follow the stem cells with medical imaging. The momentum provided by references like these make it exciting to work with business development for the nano portfolio,” says Sarah Fredriksson, CEO of Genovis AB.

<http://jnm.snmjournals.org/content/early/2012/02/09/jnumed.111.092437.abstract>

The Sentinel Node project is interdisciplinary and the goal for Genovis is to produce a multimodal particle that will be used to diagnose (using medical imaging) extremely small tumors that may quickly spread to nodes, as seen in breast cancer and melanoma. Tumor cells are spread via the lymphatic system according to a certain pattern. The first lymph node to receive this drainage is the “gatekeeper” or “sentinel” node – which is also the name of the development project that Genovis is conducting in collaboration with the Department of Medical Radiation Physics at Lund University. During the period the project focused on how much sentinel node imaging can be improved by optimizing the design of the nanostructures. The final goal of the project is to produce a contrast agent that can be used both for diagnostics and as an aid during surgery. The project is financed by the Swedish Research Council and LMK Industri AB.

About Genovis

Genovis develops and sells innovative technologies from two unique product portfolios. The first includes enzymes that facilitate development and quality control for applications such as antibody-based drugs. The products launched to date are aimed at customers who work with development of drugs, new diagnostic methods and basic research.

The second consists of nanotechnology in new contrast agents and focuses on design, production and characterization of nanostructures as contrast agents in medical imaging. The nanostructures and methods that Genovis focuses on can also be used as carriers of various substances in the development of new drug delivery methods. The projects are mainly in-house, but also include collaborations with research groups, including at Lund University.

Genovis shares are listed on the First North OMX Nordic Exchange and Thenberg fondkommission is our certified advisor.

For additional information please contact:

Sarah Fredriksson, CEO of Genovis AB

Tel: +46 (0)46-10 12 35,

e-mail: sarah.fredriksson@genovis.com